Cardiovascular disease remains a significant health challenge today. Thanks to advancements in science, innovation, and organized healthcare, we've made great strides in combating sudden cardiovascular events, saving numerous lives. However, factors like aging, lifestyle changes, and diabetes contribute to a rise in chronic heart conditions. By 2030, nearly 2 million people in the Netherlands—33% more than today—will be affected.

In response, the Dutch CardioVascular Alliance (DCVA) was formed. By bringing together twenty-four leading organisations, including patient representatives, researchers, healthcare providers, funders and industry, the DCVA aims to tackle this challenge.

We’re close to reaching our goal. Advancements in technology, such as medical big data, high-resolution imaging, molecular diagnostics, biotechnology, high-throughput sequencing, home automation, sensors, and more, are creating opportunities for early detection and personalized prevention and intervention. We plan to allocate 1 billion euros by 2030.

We've built a solid foundation, but we see greater potential for impact in the Dutch cardiovascular community by forming consortia focused on health, social, and economic outcomes. To achieve our goals, the DCVA supports its partners in establishing an exceptional and enduring environment for cardiovascular innovations, with a focus on six key priorities.

With a small team, the DCVA supports strong partnerships between DCVA partners leveraging funding and capacity for more impactful collaborations. The daily management of the DCVA is performed by the Program Management Team.  The DCVA partners are united in the Partner Assembly.  The efforts of DCVA partners are focused on six key priorities, organised in the six pillars, each chaired by a pillar chair. Together with the Program Management Team, the pillar chairs form the Steering Group.